Monoclonal Antibodies for the S2 Subunit of Spike of SARS-CoV Cross-React With the Newly-Emerged SARS-CoV-2

doi 10.1101/2020.03.06.980037
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cold Spring Harbor Laboratory

Related search

On the Interactions of the Receptor-Binding Domain of SARS-CoV-1 and SARS-CoV-2 Spike Proteins With Monoclonal Antibodies and the Receptor ACE2

2020English

Human Monoclonal Antibodies Block the Binding of SARS-CoV-2 Spike Protein to Angiotensin Converting Enzyme 2 Receptor

2020English

Dark Proteome of Newly Emerged SARS-CoV-2 in Comparison With Human and Bat Coronaviruses

2020English

Differential Antibody Recognition by Novel SARS-CoV-2 and SARS-CoV Spike Protein Receptor Binding Domains: Mechanistic Insights

2020English

Potent Human Monoclonal Antibodies Against SARS CoV, Nipah and Hendra Viruses

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2009English

SARS-COV-2 and Infectivity

Journal of Medical Virology
VirologyInfectious Diseases
2020English

Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain

2020English

In Silico Study of the Spike Protein From SARS-CoV-2 Interaction With ACE2: Similarity With SARS-CoV, Hot-Spot Analysis and Effect of the Receptor Polymorphism

2020English

Fully Human Single-Domain Antibodies Against SARS-CoV-2

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy